3'-氟-5'-(三氟甲氧基)苯乙酮 | 1352999-53-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3'-氟-5'-(三氟甲氧基)苯乙酮
• 英文名称: 1-(3-fluoro-5-(trifluoromethoxy)phenyl)ethan-1-one
• 英文别名: 3-fluoro-5-trifluoromethoxy acetophenone；3'-Fluoro-5'-(trifluoromethoxy)acetophenone；1-[3-fluoro-5-(trifluoromethoxy)phenyl]ethanone
• CAS: 1352999-53-1
• 化学式: C₉H₆F₄O₂
• 分子量: 222.139
• InChiKey: VOBVUHOUGRWDOZ-UHFFFAOYSA-N

物化性质

• 沸点：
  185.0±35.0 °C(Predicted)
• 密度：
  1.341±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3'-氟-5'-(三氟甲氧基)苯乙酮 在 溶剂黄146 、 lithium tert-butoxide 作用下， 以 四氢呋喃 为溶剂， 反应 23.5h， 生成 benzyl 5-(3-fluoro-5-(trifluoromethoxy)phenyl)-1-(5-(trifluoromethyl)pyridin-3-yl)-1H-pyrazole-3-carboxylate
  参考文献：
  名称：

  THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE

  摘要：

  本发明的一个目的是提供糖尿病、肥胖症或糖尿病并发症的治疗或预防。本发明提供了一种治疗或预防糖尿病、肥胖症或糖尿病并发症的药物，其特点是联合使用SGLT1抑制剂和至少一种从SGLT2抑制剂和DPP4抑制剂中选择的药物；以及一种治疗或预防糖尿病、肥胖症或糖尿病并发症的治疗方法，其特点是给予SGLT1抑制剂和至少一种从SGLT2抑制剂和DPP4抑制剂中选择的药物。

  公开号：

  EP4026564A1

文献信息

• CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF
  申请人：AiCuris GmbH & Co. KG

  公开号：US20150105388A1

  公开（公告）日：2015-04-16

  This invention relates to new carboxamide-substituted heteroaryl-pyrazoles, method for their production, their use for the treatment and/or prophylaxis of diseases, as well as their use for the production of pharmaceutical agents for the treatment and/or prophylaxis of diseases, in particular retroviral diseases, in humans and/or animals.

  本发明涉及新的羧酰胺取代的杂环基吡唑啉，其生产方法，它们用于治疗和/或预防疾病，以及它们用于生产用于治疗和/或预防疾病的药物制剂，特别是用于治疗和/或预防人类和/或动物的逆转录病毒性疾病。
• TRIS(HETERO)ARYLPYRAZOLES AND USE THEREOF
  申请人：AICURIS GMBH & CO. KG

  公开号：US20150203500A1

  公开（公告）日：2015-07-23

  The present invention relates to new tri(hetero)aryl pyrazoles, methods for their preparation, their use for treating and/or preventing diseases as well as their use in the preparation of drugs for treating and/or preventing diseases, in particular retroviral diseases in humans and/or animals.

  本发明涉及新的三(杂)芳基吡唑，其制备方法，其用于治疗和/或预防疾病以及其在制备用于治疗和/或预防疾病的药物中的应用，特别是用于人类和/或动物的逆转录病毒性疾病。
• PYRAZOLE COMPOUNDS SUBSTITUTED WITH HETEROARYL AND PHARMACEUTICAL USE THEREOF
  申请人：Japan Tobacco Inc.

  公开号：US20190330193A1

  公开（公告）日：2019-10-31

  Pyrazole compounds substituted with heteroaryl or pharmaceutically acceptable salts thereof that have an SGLT1 inhibitory activity and are useful for a drug, pharmaceutical compositions comprising the same, and pharmaceutical use thereof are disclosed. Specifically, a compound of Formula [X]: wherein R 1 is hydrogen or halogen, R 2 is C 1-6 alkyl or halo-C 1-6 alkyl, Ring Het is substituted pyridyl or optionally substituted pyrazinyl, pyrimidinyl, or pyridazinyl, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising it, and pharmaceutical use thereof is provided.

  揭示了具有SGLT1抑制活性的以杂环芳基取代的吡唑化合物或其药学可接受的盐，用作药物，包括它们的药物组合物，以及其药用。具体地，提供了以下式[X]的化合物：其中R1为氢或卤素，R2为C1-6烷基或卤代C1-6烷基，环Het为取代的吡啶基或可选择取代的吡嗪基、嘧啶基或吡啉基，或其药学可接受的盐，包括它的药物组合物和药用。
• Tris(hetero)arylpyrazoles and use thereof
  申请人：AICURIS GMBH & CO. KG

  公开号：US09249148B2

  公开（公告）日：2016-02-02

  The present invention relates to new tri(hetero)aryl pyrazoles, methods for their preparation, their use for treating and/or preventing diseases as well as their use in the preparation of drugs for treating and/or preventing diseases, in particular retroviral diseases in humans and/or animals.

  本发明涉及新的三(杂)芳基吡唑，其制备方法，它们用于治疗和/或预防疾病的用途，以及它们在制备用于治疗和/或预防疾病的药物中的用途，特别是用于治疗和/或预防人类和/或动物的逆转录病毒性疾病。
• THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE
  申请人：Japan Tobacco Inc.

  公开号：EP4026564A1

  公开（公告）日：2022-07-13

  One purpose of the present invention is to provide therapy or prophylaxis of diabetes, obesity, or diabetic complications. The present invention provides a therapeutic or prophylactic medicine that is for diabetes, obesity, or diabetic complications, and that is characterized by combinational use of an SGLT1 inhibitor and at least one drug selected from SGLT2 inhibitors and DPP4 inhibitors; and a therapeutic or prophylactic method that is for diabetes, obesity, or diabetic complications, and that is characterized by administering an SGLT1 inhibitor and at least one drug selected from SGLT2 inhibitors and DPP4 inhibitors.

  本发明的一个目的是提供糖尿病、肥胖症或糖尿病并发症的治疗或预防。本发明提供了一种治疗或预防糖尿病、肥胖症或糖尿病并发症的药物，其特点是联合使用SGLT1抑制剂和至少一种从SGLT2抑制剂和DPP4抑制剂中选择的药物；以及一种治疗或预防糖尿病、肥胖症或糖尿病并发症的治疗方法，其特点是给予SGLT1抑制剂和至少一种从SGLT2抑制剂和DPP4抑制剂中选择的药物。